Hughes Institute Moves To Bolster Female And Minority Participation

When scientists accept a nomination to become Howard Hughes Medical Institute (HHMI) investigators, they become employees of HHMI, receiving full financial support for salary, staff, and equipment in renewable appointments of three, five, or seven years. However, HHMI investigators--who conduct their work at universities and medical centers across the United States-- still maintain their institutional appointments. Under a collabo

Written byKaren Kreeger
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

When scientists accept a nomination to become Howard Hughes Medical Institute (HHMI) investigators, they become employees of HHMI, receiving full financial support for salary, staff, and equipment in renewable appointments of three, five, or seven years. However, HHMI investigators--who conduct their work at universities and medical centers across the United States-- still maintain their institutional appointments. Under a collaborative agreement between these institutions and HHMI, investigators must spend 75 percent of their time doing research, while the other 25 percent can be devoted to activities such as teaching, mentoring graduate students, and serving on committees. In return, the investigators receive support for themselves, research technicians, and post- doctoral fellows. HHMI also pays for administrative services and laboratory overhead and supplies. Institute officials say the number of new female appointees for this year will nearly double the current roster of 25 women who are HHMI investigators. At the same time, the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies